Citations

Abstract Introduction Cystoid macular edema (CME) is a recognized complication associated with penetrating keratoplasty (PK) and Endothelial Keratoplasty (EK). The purpose of this study was to determine the incidence of acute CME within the first 6 months after PK, Descemet stripping automated EK, or Descemet’s membrane EK. Methods A retrospective cohort analysis of the TriNetX United States collaborative database was conducted. Patients with a diagnosis of Fuchs dystrophy or keratoconus who underwent PK or EK between January 1, 2004 and August 30, 2024 were included. Those with a history of uveitis, retinal vascular occlusion, diabetic macular edema, or prior vitrectomy were excluded. Outcomes and diagnoses were defined using current procedural terminology and International Classification of Diseases, Tenth edition (ICD-10) codes. Cohorts were stratified based on a history of prior PK or EK with >6 months follow-up. Propensity score matching was performed on both cohorts to control for age at index, sex, race, ethnicity, and the diagnosis of Fuchs dystrophy and keratoconus. The incidence of acute CME during a 6-month postoperative follow-up period was assessed. Odds ratios were calculated between cohorts. Results A total of 2516 eyes were included in the study (PK: 1258; EK: 1258). At six months postoperatively, the incidence of acute CME in the EK cohort (46 of 1258) was significantly higher than in the PK cohort (20 of 1258) (P = 0.0012) (OR 0.426, 95% confidence interval 0.25–0.72). Conclusions Our findings suggest that the incidence of acute CME is higher in patients undergoing EK compared to PK.

Purpose: To compare the safety and efficacy of gonioscopy-assisted transluminal trabeculotomy (GATT) combined with phacoemulsification in eyes with high myopia versus non-high myopia with open-angle glaucoma. Methods: This retrospective comparative study included 76 eyes with open-angle glaucoma. Eyes were stratified into high myopia (Group 1; axial length ≥26.5 mm, n = 36) and non-high myopia (Group 2; axial length <26.5 mm, n = 40). Baseline parameters including intraocular pressure (IOP), best-corrected visual acuity, and number of anti-glaucoma medications (AGMs) were compared at 2 weeks, 1 month, and 3, 6, and 12 months. Surgical success was defined as IOP ≤21, ≤18, or ≤15 mmHg with a ≥20%, ≥25%, or ≥30% reduction from baseline, respectively. Postoperative complications, secondary interventions, and surgical risk factors were analyzed. Results: The mean (SD) IOP (mmHg) decreased from 20.56 ± 4.71 to 13.32 ± 5.02 in Group 1 and 19.33 ± 4.15 to 12.94 ± 3.48 in Group 2 at 12 months, with no significant difference between groups ( P = 0.92). AGM reduced from 2.11 ± 0.89 to 0.36 ± 0.95 in Group 1 and 1.98 ± 0.89 to 0.06 ± 0.24 in Group 2 at 12 months ( P = 0.07). There was no significant difference in success rate between groups by all criteria at the end of 12 months ( P = 0.77, 0.54, 0.14). Transient hyphema and IOP spikes were common complications. Five eyes required anterior chamber wash (3 in Group 1, 2 in Group 2). Conclusion: GATT with phacoemulsification is a safe and effective procedure in high myopia with open-angle glaucoma, with comparable outcomes to non-high myopia eyes at 12 months.

Abstract Purpose: To explore the potential of the metaverse, a three-dimensional platform merging physical and virtual realities (VRs), in advancing the field of ophthalmology. This study examines its applications in areas such as VR-based surgical training, augmented reality (AR)-assisted surgeries, artificial intelligence (AI)-driven diagnostics, and teleophthalmology. This review builds upon previous literature by integrating recent evidence and technological advancements, offering a more comprehensive analysis of particular applications and barriers in ophthalmology. Methods: Academic literature published between 2019 and 2024 was identified through searches in the PubMed database and Google Scholar search engine using relevant keywords. This review focused on studies discussing the application of the metaverse in health care and ophthalmology, with particular attention to key trends, emerging uses, technological features, and associated challenges. Results: A total of 60 studies were deemed relevant for inclusion in this review. The infrastructure supporting the Metaverse comprises technologies such as the Internet of Things, digital twins, mirror worlds, nonfungible tokens, blockchain technology, and lifelogging. Together, these technologies create immersive environments that users can access through VR headsets, AR glasses, and handheld controllers. The metaverse presents promising opportunities in ophthalmology, particularly in enhancing clinical training through simulators such as the EyeSi™ surgical simulator, VRmagic EyeSi Slit Lamp, and the HelpMeSee™ VR simulator. In addition, it facilitates remote consultations and improves diagnostic and treatment options, exemplified by tools such as the Vivid Vision™ system for amblyopia, the Microsoft HoloLens™ for navigating complex anatomical structures, and AI-based platforms for the early detection of diseases such as glaucoma and diabetic retinopathy. Furthermore, the metaverse may enhance patient education by simulating the visual effects of ophthalmic conditions and visualizing postoperative outcomes. However, challenges, including financial limitations, data security concerns, and cultural acceptance, must be addressed. Conclusions: A gradual and context-specific integration of the metaverse is essential, particularly in underdeveloped regions. As the metaverse evolves, it holds significant potential to transform the field of ophthalmology by promoting global collaboration and innovation, complementing traditional practices, and ensuring equitable access to advanced healthcare solutions.

Abstract Purpose: The purpose of the study was to evaluate the efficacy of Sustained-release Intravitreal Dexamethasone implant (Ozurdex; Allergan Inc., Irvine, CA) during vitrectomy in preventing proliferative vitreoretinopathy (PVR). Methods: Double-blind, prospective, randomized, placebo-controlled trial. Eighty consecutive patients diagnosed with rhegmatogenous retinal detachment with high-risk PVR were randomized to study and control groups ( n = 40 each). Study group/Adjunct group (group 1) patients underwent vitrectomy with Sustained-release Intravitreal Dexamethasone implant (0.7 mg). In the control group (group 2), a similar surgery was performed without the use of a dexamethasone implant. Patients were evaluated at 1 month, 3 months, and 6 months after surgery. Postoperative retinal reattachment, recurrence of PVR, best-corrected visual acuity, and complications at the end of 6 months were compared between the two groups. Results: At 6 months postsurgery, 68.7% of patients had reattached retina. There was no significant difference ( P > 0.05) in retinal reattachment in both of the groups. The rate of postoperative PVR in the control group was 56%; in the study group, the rate was 46% ( P > 0.05), which proves statistically insignificant. In addition, there was no statistically significant difference in visual outcomes between the two groups ( P > 0.05), and no significant difference in the complication rate and drug toxicity was noted between the two groups. At 6 months, fewer adjunct patients had Cystoid macular edema or a foveal thickness of >300 μm compared with controls ( P = 0.003, P = 0.031). Conclusions: This study fails to prove the efficacy of the intraoperative use of Sustained-release Intravitreal Dexamethasone implant for the prevention of postoperative PVR or improvement in final visual acuity but it does reduce inflammation and CME. At the same time, no significant complications could be attributed to the treatment.

A systematic review was conducted of studies published up to 30 August 2024. Studies comparing conventional visual field (VF) indices, ability to detect central visual field defects (CVFDs), structure–function (S-F) concordance, and test characteristics across the HVF 24-2C SITA-Faster, 24-2 SITA-Standard/Faster, and 10-2 SITA-Standard/Fast tests were included. Eight studies with 1239 subjects (49.1% male; mean age, 54.8–66.9 years) were analyzed. The 24-2C produced similar global VF indices compared to the 10-2 and 24-2 (Standard/Faster) (ICC = 0.95 and 0.80, p < 0.001), detected more VF defects and CVFD clusters, and demonstrated greater S-F concordance than the 24-2 (Standard/Faster). Although the 10-2 (Standard/Fast) detected significantly more CVFDs and had a greater S-F concordance, the agreement between the 24-2C and 10-2 grids was substantial (ĸ = 0.488 to 0.708). The 24-2C was also faster compared to the 24-2 Standard and 10-2 (Standard/Fast), with comparable false positives, higher false negatives, and fewer fixation losses than the 24-2 Standard. In conclusion, the HVF 24-2C is quicker and identifies more CVFDs than the 24-2 grid, demonstrates high agreement with the 10-2 grid, and aids in CVFD screening.

Abstract In this study, we quantified differences in iris stiffness between female and male subjects in healthy and postlaser peripheral iridotomy (post-LPI) groups using an image-based inverse modeling approach. We analyzed anterior segment optical coherence tomography (AS-OCT) images from 25 participants across four groups. Finite element models were created using **solidworks, **abaqus, and a custom C program, modeling the iris as a neo-Hookean material. We found that post-LPI females had significantly higher normalized elastic modulus (E′=3.81±1.74) than healthy females (E′=0.92±0.31,p=0.004), while no significant difference was observed in males. Post-LPI females also showed significantly higher stiffness than post-LPI males (p=0.003). Here, p denotes the probability value, with p&lt;0.05 considered statistically significant. Our findings suggest that sex-based differences in iris biomechanics may contribute to the higher susceptibility of females to primary angle-closure disease. Despite the small sample size, this preliminary study highlights the need for larger, sex-stratified investigations into glaucoma pathophysiology.

Précis: ASOCT features of greater bleb height, thicker bleb walls, and lower reflectivity are associated with trabeculectomy success, supporting the ASOCT’s utility in monitoring and predicting outcomes postsurgery through standardized imaging protocols. Purpose: To evaluate and quantify the relationship between bleb characteristics on ASOCT with surgical outcomes. Methods: A literature search was conducted across Medline, Embase, Cochrane, and Scopus for studies from the past 20 years, until 16 September 2024, on “glaucoma,” “trabeculectomy,” and “ASOCT.” Data collected included patient characteristics, each study’s definition of bleb success, clinical outcomes, as well as bleb characteristics. A literature review was conducted on studies that could not be used for meta-analysis. Results: Eleven studies, with a pooled total of 528 eyes in 517 patients, were included in the final meta-analysis. Successful blebs had significantly higher mean bleb height [mean difference (MD) 0.38 mm, 95% CI: 0.20-0.56 mm, P=0.002], greater maximum bleb wall thickness (MD: 0.21 mm, 95% CI: 0.07-0.35 mm, P=0.009), and decreased reflectivity (MD: −48.9%, 95% CI: −78.3 to −19.4%, P=0.010), compared with failed blebs. No significant differences were found in bleb fluid cavity height and bleb area. Narrative synthesis revealed that wider blebs, increased fluid-filled cavity height, increased number of microcysts, larger filtration opening widths, and multiform bleb walls were also associated with higher rates of bleb success. Early bleb parameters were statistically significant predictors of bleb success up to 12 months postoperatively. Conclusions: Greater bleb height, thicker bleb walls, and lower reflectivity on ASOCT are consistently associated with successful trabeculectomy outcomes. The ASOCT may be useful in predicting bleb success and in supplementing postoperative monitoring, hence guiding timely medical or procedural interventions, to ensure long-term bleb success.

Objective To evaluate the safety and efficacy of MicroPulse Transscleral Laser Therapy (MicroPulse TLT) with the Revised P3 ® Delivery Device. Design Prospective, single-surgeon, interventional study in a tertiary hospital setting. Participants Sixty-two eyes of 40 patients with refractory glaucoma. Methods All subjects received 360-degree MicroPulse TLT treatment (2500 mW, 31.33% duty cycle) over a total of 240 s (8 sweeps; n = 20), 300 s (10 sweeps; n = 22), or 200 s (10 sweeps; n = 20). Participants were followed up for 6 months to assess changes in intraocular pressure (IOP), glaucoma medication burden, and best-corrected visual acuity (BCVA). Surgical success was defined as a reduction of IOP ≥ 30% from baseline and between 6–18 mmHg at last follow-up with no additional anti-glaucoma medications or secondary reinterventions. Results Surgical success was achieved in 72.7% (300 s group), 75.0% (240 s group), and 80.0% (200 s group) of eyes. Mean IOP was significantly reduced ( p < 0.001) by 49.0% (300 s group), 45.66% (240 s group), and 39.8% (200 s group) at 6 months. With all groups combined, the mean number of glaucoma medications was significantly reduced by 17.8% ( p = 0.005), and no significant changes in BCVA were observed at 6 months. Complications were minimal, including four eyes with IOP spikes, one eye with hyphema, and one eye with cystoid macular edema (CME), all of which resolved. Two eyes of the total sample (3.2%) required secondary glaucoma surgery before 6 months. Conclusions Second-generation MicroPulse TLT at fluence values of 154–229 J/cm 2 appears to be a safe and effective option for IOP reduction in refractory glaucoma.